BioSpace News Archive

AdventHealth Tampa is proud to announce the accreditation of its new Obstetrics and Gynecology Residency Program, helping improve access to women’s healthcare in the Tampa Bay region.

The New England Journal of Medicine published detailed results from Eli Lilly and Company’s phase 2a study of peresolimab in rheumatoid arthritis, in which peresolimab met the primary endpoint for efficacy and had similar rates of adverse events between peresolimab and placebo arms.

BD (Becton, Dickinson and Company) announced the worldwide commercial launch of a new-to-world cell sorting instrument featuring two breakthrough technologies that enable researchers to uncover more detailed information about cells that was previously invisible in traditional flow cytometry experiments.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that management will participate in the A.G.P. Virtual Healthcare Conference and host investor meetings.

Orchard Therapeutics today presented new data from the company’s hematopoietic stem cell (HSC) gene therapy research pipeline targeting larger indications at the ongoing 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles.

EyePoint Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement for the sale of YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences, Inc. (“Alimera”).

PepGen Inc. today announced that the company has received a No Objection Letter (NOL) for its Clinical Trial Application (CTA) from Health Canada for its Phase 2 CONNECT1-EDO51 study to initiate an open label, multiple ascending dose (MAD) clinical trial of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) amenable to an exon 51 skipping approach.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported interim results from a previously published prospective, randomized study more than 1,000 patients aimed at evaluating the clinical utility of the ExoDx™ Prostate Test over a 5-year follow-up period.

Bodyport Inc. today introduced SCALE-HF, a multi-phase study to develop and validate a composite index to predict heart failure events using multiple noninvasive hemodynamic biomarkers gathered when a patient stands on the Bodyport Cardiac Scale.

Evogene Ltd. today announced its financial results for the first quarter period ending March 31, 2023.